Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
作者信息
Aksan Ayşegül, Dignass Axel, Stein Jürgen
机构信息
Interdisciplinary Crohn Colitis Clinical Center Rhein-Main, 60594, Frankfurt am Main, Germany.
Department of Pharmaceutical Chemistry, University of Frankfurt, 60590, Frankfurt am Main, Germany.
出版信息
Adv Ther. 2019 Aug;36(8):1817-1820. doi: 10.1007/s12325-019-00990-x. Epub 2019 Jun 1.
Abstract
摘要
相似文献
1
Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.信函：丹麦炎症性肠病合并缺铁性贫血患者中异麦芽糖酐铁1000与羧基麦芽糖铁的经济学评价
Adv Ther. 2019 Aug;36(8):1817-1820. doi: 10.1007/s12325-019-00990-x. Epub 2019 Jun 1.
2
Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.回应：丹麦炎性肠病合并缺铁性贫血患者中异麦芽糖酐铁1000与羧基麦芽糖铁的经济学评价
Adv Ther. 2019 Aug;36(8):1821-1825. doi: 10.1007/s12325-019-00993-8. Epub 2019 Jun 1.
3
An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.丹麦炎性肠病伴缺铁性贫血患者用异麦芽糖铁 1000 与羧基麦芽糖铁进行经济学评价。
Adv Ther. 2018 Dec;35(12):2128-2137. doi: 10.1007/s12325-018-0827-5. Epub 2018 Nov 19.
4
Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.铁羧基麦芽糖铁或葡萄糖酸亚铁治疗炎症性肠病患者的低磷血症发生率。
Aliment Pharmacol Ther. 2019 Aug;50(4):397-406. doi: 10.1111/apt.15386. Epub 2019 Jul 2.
5
Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK.静脉铁剂治疗炎症性肠病缺铁性贫血：英国异麦芽糖酐 1000（Monofer）治疗缺铁性贫血的预算影响分析。
Expert Opin Drug Deliv. 2017 Dec;14(12):1439-1446. doi: 10.1080/17425247.2017.1393412. Epub 2017 Oct 24.
6
Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.铁状态以及评估羧基麦芽糖铁治疗炎症性肠病患者的疗效和安全性的分析。
Digestion. 2012;85(1):47-54. doi: 10.1159/000333091. Epub 2011 Dec 14.
7
A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain.西班牙缺铁性慢性心力衰竭患者使用羧基麦芽糖铁的成本效益分析
Rev Esp Cardiol (Engl Ed). 2015 Oct;68(10):846-51. doi: 10.1016/j.rec.2014.10.010. Epub 2015 Jan 28.
8
Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study.炎症性肠病缺铁患者单次输注英夫利昔单抗后立即使用羧基麦芽糖铁的安全性：一项初步研究。
PLoS One. 2015 May 26;10(5):e0128156. doi: 10.1371/journal.pone.0128156. eCollection 2015.
9
The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective.静脉铁治疗在 IBD 患者中的医疗费用取决于经济评价视角。
J Crohns Colitis. 2010 Oct;4(4):427-30. doi: 10.1016/j.crohns.2010.01.007. Epub 2010 Feb 16.
10
Letter to the editor: in response to: Richard F Pollock & Patrick Biggar. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia.致编辑的信：回应：理查德·F·波洛克和帕特里克·比加尔。右旋糖酐铁、蔗糖铁和羧基麦芽糖铁治疗缺铁性贫血安全性的间接比较方法。
Expert Rev Hematol. 2022 Apr;15(4):383-384. doi: 10.1080/17474086.2021.1883948. Epub 2021 Feb 10.
本文引用的文献
1
An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.丹麦炎性肠病伴缺铁性贫血患者用异麦芽糖铁 1000 与羧基麦芽糖铁进行经济学评价。
Adv Ther. 2018 Dec;35(12):2128-2137. doi: 10.1007/s12325-018-0827-5. Epub 2018 Nov 19.
2
The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency.NIMO斯堪的纳维亚研究：一项关于缺铁患者使用异麦芽糖铁治疗的前瞻性观察研究。
Gastroenterol Res Pract. 2017;2017:4585164. doi: 10.1155/2017/4585164. Epub 2017 Oct 22.
3
Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease.系统评价与网络荟萃分析：比较不同静脉用铁剂治疗炎症性肠病患者缺铁性贫血的疗效和耐受性。
Aliment Pharmacol Ther. 2017 May;45(10):1303-1318. doi: 10.1111/apt.14043. Epub 2017 Mar 21.
4
FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.FERGIcor 研究：一项评估羧基麦芽糖铁治疗炎症性肠病缺铁性贫血的随机对照试验
Gastroenterology. 2011 Sep;141(3):846-853.e1-2. doi: 10.1053/j.gastro.2011.06.005. Epub 2011 Jun 12.
5
Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment.静脉注射蔗糖铁和促红细胞生成素治疗后，炎症性肠病相关贫血和缺铁迅速复发。
Am J Gastroenterol. 2009 Jun;104(6):1460-7. doi: 10.1038/ajg.2009.114. Epub 2009 Apr 21.
Zotero 插件